Eli Lilly CEO Says Science Will Win in Covid Fight

The video discusses the current state of vaccine and treatment development for COVID-19, focusing on monoclonal antibodies and various vaccine approaches. It highlights the challenges in scaling up production and the economic considerations of pricing and profitability. The discussion emphasizes the importance of scientific efforts and collaboration in addressing the pandemic.

What is the primary focus of monoclonal antibody treatments discussed in the video?

• Developing a new vaccine

• Preventing COVID-19 infection

• Treating early-stage COVID-19

• Enhancing immune response in healthy individuals

Which new technology is being explored for COVID-19 vaccine development?

• DNA-based vaccines

• Protein subunit vaccines

• mRNA vaccines

• Live attenuated vaccines

What is a significant challenge in scaling up antibody therapies?

• Limited global manufacturing infrastructure

• High cost of distribution

• Lack of raw materials

• Insufficient clinical trials

What is the primary goal regarding patient costs for COVID-19 therapies?

• To ensure patients pay nothing

• To charge a premium for high-risk patients

• To offer discounts for bulk purchases

• To provide free samples to healthcare providers

How does the company plan to create value with its pricing strategy?

• By increasing the price gradually over time

• By maximizing profit margins

• By reducing direct healthcare costs

• By offering rebates to insurance companies

What is the expected impact of the COVID-19 therapies on hospitalization risk?

• Reduce by 20-30%

• No change

• Increase by 50%

• Reduce by 70-80%

What is the company's stance on the profitability of COVID-19 therapies?

• They expect modest returns

• They expect high profitability

• They expect no returns

• They expect losses